After dealing with a deployment issue with glucose monitors earlier this year, interim CEO Jake Leach said improving customer ...

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

DexCom Inc (DXCM) reports a robust 22% increase in worldwide revenue, driven by expanded CGM access and strategic market ...

Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales ...

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

Get key insights from DexCom’s Q3 2025 earnings: robust revenue growth, new product launches, updated guidance, and future opportunities.

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.

Investing.com -- DexCom (NASDAQ:DXCM) stock fell 4% Tuesday after a concerning report from Hunterbrook detailed multiple deaths allegedly linked to the company’s G7 continuous glucose monitor.

DexCom was named a Barron’s stock pick in July. After DexCom shifted its focus to the Type 2 population last year, Type 1 ...

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) securities during ...

Dexcom Inc. executives may have thought a $30 million beat ... following issues with its G7 sensor, which management said have been largely resolved.